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reduced by 1.1% in PHEP, and total MU for PHEP was 1.8% lower than 
that for LEP. In the P-NTV, the Dmean, V20Gy and V25Gy of the PHEP were 
1.6%, 1.8% and 2.9% lower than those of LEP. 
Conclusions: Dose to some OARs and a normal tissue, total monitor 
unit were reduced in IMRT plan with partially used high ergy photon. 
Although these reduction are unclear how have a clinical benefit to 
patient, application of the partially used high energy photon could 
improve the overall plan quality of IMRT for head and neck cancer. 
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Purpose/Objective: To assess the practical feasibility of IMRT 
treatment planning and delivery for single dose palliative radiotherapy 
in spinal bone metastases limiting adverse effects as vomiting, nausea 
and diarrhea. 
Materials and Methods: Target volumes and critical structureswere 
delineated. IMRT plans were created using RayStation (RaySearch, 
Stockholm) for 36 patients previously treated with one posterior field. 
The plans consisted of three beams with in total 9 segments at fixed 
gantry anglesof 130, 180 and 230 degrees using 6 MV photons. IMRT 
plans were compared to the conventional plans with respect to 
planning time and treatment time. Normal tissue sparing as well as 
target coverage and dose homogeneity were evaluated by dose 
volume histograms. 
Results: IMRT plans resulted in normal tissue sparing resulted from 
IMRT due to a more localized dose delivery. Dose to the kidneys was 
higher in IMRT patients, but to a level well below the QUANTEC-
tolerance limits. IMRT treatment planning results in improved target 
homogeneity.  
In the higher regionsof the spine (Th4-Th9) the esophagus still 
receives a high amount of dose.  
 
  
 
 Conclusions: Implementation of IMRT in palliative treatment of spinal 
metastases using 1x8Gy is feasible without a significant increase of 
labor or treatment time. It decreases the amount of dose in normal 
tissue that might result in acute adverse effects. The findings in this 
study should be tested to show the clinical value of lowering the dose 
in normal tissue. Other bundle designs might be investigated to lower 
the esophageal dose. Implementation of IMRT treatment planning and 
delivery thereby seems feasible in clinical practice. 
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Purpose/Objective: the primary aim to conduct a dosimetric study 
between WP-3D-CRT and WP-IMRT as regard to coverage to target 
volumes and doses to risk structures for definitive treatment of 
cervical cancer stage IB-IVA. 
Materials and Methods: 15 patients with cervical cancer stage IB-IVA 
were treated with WP-3D CRT (45Gy/25 fr/5weeks) with concomitant 
weekly cisplatin 40mg/m2 followed by one application of LDR 
brachytherapy 30 Gy to point A then parametrial boost 10-
15Gy/5Fr/1week. The patients were replanned with WP-IMRT. The 
margin was compatible with literatures and organ motion. DVHs were 
compared for the target volumes and OAS using paired t-test. 
Results: the mean target volume coverage by 95% (V42.7) was 95.78% 
for WP-3D-CRT and 93.22% for WP-IMRT (p value <0.001). IMRT was 
associated with significant dose reduction to OAS at V40 and V45 
levels. There was >20% reduction at V40 level for most of patients: 
63.52% (bladder), 16.67% (small bowel) and 37.12% (rectum). 
Conclusions: An initial IMRT plan with appropriate margin 
encompassing the target volumes and potential microscopic pelvic 
spread leads to reduction in the doses to OAS without compromising 
the target volume. while in locally advanced cases stage IIIB-IVA, 
there was a little benefit especially when large part of rectum or 
bladder were included in the target volumes.  
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Purpose/Objective: Radiotherapy quality assurance (RTQA) is now a 
requirement of radiotherapy trials since poor protocol compliance has 
been shown to impact on outcomes. We aim to determine the degree 
of variation in head and neck target contouring and the impact of 
RTQA feedback on clinician conformity using pre-accrual benchmark 
cases. 
Materials and Methods: Two trials, the first a randomised study of 
dose escalated intensity modulated radiotherapy (IMRT) verses 
standard dose IMRT in patients receiving treatment for locally 
advanced laryngeal / hypopharyngeal cancers (ART-DECO)and the 
second a study of cochlear-sparing IMRT versus conventional 
radiotherapy in patients with parotid tumours(COSTAR), require all 
prospective investigators to submit pre-accrual contouring benchmark 
cases. Cases are assessed for protocol compliance and resubmissions 
requested until trial compliant. All benchmark cases for ART-DECO 
and COSTAR until June 2012 arecollected in DICOM format. Cases were 
analysed using a tumour management group (TMG) consensus contour. 
Dice coefficient (DC), Jaccard index (JI) and geographical miss index 
(GMI) were calculated for each individual structure. The data was pre-
processed to ensure uniform structure nomenclature and then 
analysed using automated trial analysis tools built using MATLAB 
R2011a and CERR v.4.0.  
Results: By June 2012, 14 clinicians had submitted a total of 77 
exercises for the ART-DECO trial; 38 for case 1 and 39 for case 2. The 
maximum number of re-submissions was 4. For the COSTAR trial, 27 
clinicians had submitted a total of 53 benchmark cases.The maximum 
number of re-submissions was 3. A total of 700 target volume contours 
were analysed; 385 for ART-DECO (CTV1, spinal cord (SC), brainstem 
(BS), ipsilateral parotid (IP) and contralateral parotid (CP)) and 330 
for COSTAR (CTV1, SC, BS, CP, left cochlea and right cochlea). All 
conformity indices showed varying levels of conformity in clinician 
contouring. For ART-DECO exercise 1, BS had a median JI of 0.55 
(Interquartile Range (IQR) 0.11) and CTV1 had a median JI of 0.63 (IQR 
0.11). Improvements in JI were seen after each successive submission 
from individual clinicians. After submission 4 for ART-DECO exercise 1 
